Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Ib Kimyoung Co., Ltd. (339950:KRX), powered by AI.
Ib Kimyoung Co., Ltd. is currently trading at ₩2,630. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Ib Kimyoung Co., Ltd. on Alpha Lenz.
Ib Kimyoung Co., Ltd.'s P/E ratio is 5.7.
“Ib Kimyoung Co., Ltd. trades at a P/E of 5.7 (undervalued) with strong ROE of 32.2%. 3Y revenue CAGR of 11.4% highlights clear growth momentum.”
Ask for details →Ib Kimyoung Co., Ltd. is a notable name in the biotechnology and pharmaceuticals sector, primarily engaged in research, development, and commercialization of innovative therapeutic solutions. The company's core mission revolves around improving patient outcomes through cutting-edge biopharmaceutical products and technologies. Ib Kimyoung Co., Ltd. has carved a niche for itself by focusing on key therapeutic areas that address critical unmet medical needs, thus playing a pivotal role in advancing healthcare solutions. With a strong emphasis on research and development, the company invests significantly in exploring novel drug candidates and optimizing drug discovery processes. Its impact resonates across various dimensions of the healthcare industry, from providing groundbreaking treatments to enhancing the overall efficiency of healthcare delivery. In the financial markets, Ib Kimyoung Co., Ltd. serves as a crucial entity within the biopharmaceutical landscape, contributing to the dynamism of the sector. The company's innovations not only hold the potential to transform lives but also to influence market trends, fostering growth and sustainability in the healthcare domain.
“Ib Kimyoung Co., Ltd. trades at a P/E of 5.7 (undervalued) with strong ROE of 32.2%. 3Y revenue CAGR of 11.4% highlights clear growth momentum.”
Ask for details →Ib Kimyoung Co., Ltd. (ticker: 339950) is a company listed on KRX in the Financial Services sector (Shell Companies). It has approximately 317 employees. Market cap is $118.2B.
The current price is ₩2,630 with a P/E ratio of 5.71x and P/B of 1.6x.
ROE is 32.19% and operating margin is 15.96%. Annual revenue is $119.5B.